SCHEDULE 13G/A: Samlyn Capital Discloses Continued 6.0% Stake in Corvus Pharmaceuticals

Samlyn Capital, LLC, along with Samlyn, LP and Robert Pohly, has filed an Amendment No. 4 to Schedule 13G, reaffirming a 6.0% beneficial ownership stake in Corvus Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly collectively reported beneficial ownership of 4,065,935 shares of Corvus Pharmaceuticals, Inc. Common Stock.
• This ownership represents 6.0% of the outstanding Common Stock of Corvus Pharmaceuticals, Inc.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The reporting persons hold these shares with shared voting power and shared dispositive power.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
• The reported shares are directly owned by advisory clients of Samlyn Capital, LLC, with no single advisory client beneficially owning more than 5% of the Common Stock.

Sentiment

Score: 5

Explanation: This is a neutral, factual regulatory filing disclosing beneficial ownership. It does not contain information that would significantly alter sentiment positively or negatively regarding the issuer's performance or prospects.

Positives

• No specific positives related to company performance or strategy are disclosed in this ownership filing.

Negatives

• No specific negatives related to company performance or strategy are disclosed in this ownership filing.

Risks

• No specific risks related to Corvus Pharmaceuticals' operations or financial health are disclosed in this ownership filing.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Corvus Pharmaceuticals' future outlook.

Management Comments

• This filing does not contain comments from Corvus Pharmaceuticals' management.

Industry Context

This filing reflects a routine disclosure of significant beneficial ownership by an institutional investor, Samlyn Capital, in a biotechnology company, Corvus Pharmaceuticals. Such disclosures are common and indicate ongoing institutional investment activity within the sector.

Comparison to Industry Standards

• This filing does not contain performance data or specific metrics that allow for a direct comparison to industry standards or comparable companies.

Stakeholder Impact

• Provides transparency to shareholders regarding significant institutional ownership.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for Corvus Pharmaceuticals.

Key Dates

Keywords

Corvus Pharmaceuticals, Samlyn Capital, Robert Pohly, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology